Treating ALK-positive lung cancer-early successes and future challenges

Nature Reviews Clinical Oncology

Volumn 9, Issue 5, 2012, Pages 268-277

  Camidge, D Ross ^a   Doebele, Robert C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; PEMETREXED;

ALK GENE; BRADYCARDIA; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EDEMA; ENZYME ACTIVATION; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPERTRANSAMINASEMIA; HYPOGONADISM; HYPOPHOSPHATEMIA; KIDNEY CYST; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SARCOMA; SIDE EFFECT; STOMATITIS; VISUAL DISORDER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84860352732     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.43     Document Type: Review

References (99)

1. Le Beau, M. M. et al. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki1positive anaplastic large cell lymphoma. Leukemia 3, 866-870 (1989). (Pubitemid 20003685)
2. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994). (Pubitemid 24107549)
3. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
4. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
5. Crinò, L. et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract]. J. Clin. Oncol. 29 (Suppl.), a7514 (2011).
6. Iwahara, T. et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439-449 (1997). (Pubitemid 27087107)
7. Morris, S. W. et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14, 2175-2188 (1997). (Pubitemid 27248229)
8. Vernersson, E. et al. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 6, 448-461 (2006). (Pubitemid 43843121)
9. Lorén, C. E. et al. Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells 6, 531-544 (2001). (Pubitemid 32655385)
10. Lorén, C. E. et al. A crucial role for the anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO Rep. 4, 781-786 (2003). (Pubitemid 37063186)
11. Lee, H. H., Norris, A., Weiss, J. B. & Frasch, M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 425, 507-512 (2003). (Pubitemid 37237045)
12. Englund, C. et al. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 425, 512-516 (2003). (Pubitemid 37237046)
13. Bazigou, E. et al. Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell 128, 961-975 (2007). (Pubitemid 46341423)
14. Souttou, B., Carvalho, N. B., Raulais, D. & Vigny, M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 276, 9526-9531 (2001).
15. Mossé, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
16. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
17. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
18. George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
19. Murugan, A. K. & Xing, M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71, 4403-4411 (2011).
20. Webb, T. R. et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev. Anticancer Ther. 9, 331-356 (2009).
21. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007). (Pubitemid 350235027)
22. Takeuchi, K. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143-3149 (2009).
23. Gascoyne, R. D. et al. ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of 6 cases. Blood 102, 2568-2573 (2003). (Pubitemid 37193597)
24. Ma, Z. et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37, 98-105 (2003). (Pubitemid 36417927)
25. Camidge, D. R. et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 16, 5581-5590 (2010).
26. Weickhardt, A. J. & Camidge, D. R. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin. Invest. 1, 1119-1126 (2011).
27. Atherly, A. J. & Camidge, D. R. The cost effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer http://dx.doi.org/10.1038/bjc.2012.60.
28. Inamura, K. et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J. Thorac. Oncol. 3, 13-17 (2008).
29. Shaw, A. T. et al. Clinical features and outcome of patients with nonsmallcell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
30. Rodig, S. J. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15, 5216-5223 (2009).
31. Subramanian, J. & Govindan, R. Lung cancer in Never-smokers': a unique entity. Oncology (Williston Park) 24, 29-35 (2010).
32. Zhang, X. et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol. Cancer 9, 188 (2010).
33. Varella-Garcia, M. et al. ALK gene rearrangements in unselected Caucasians with non-small cell lung carcinoma (NSCLC) [abstract]. J. Clin. Oncol. a10533 (2010).
34. Yang, P. et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J. Thorac. Oncol. 7, 90-97 (2012).
35. Solomon, B. & Shaw, A. T. Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both? J. Thorac. Oncol. 7, 5-7 (2012).
36. Shaw, A. T. et al. Effect of crizotinib on overall survival in patients with advanced nonsmallcell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
37. Lee, J. K. et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer http://dx.doi.org/10.1002/cncr.26668.
38. Wu, S. G. et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J. Thorac. Oncol. 7, 98-104 (2012).
39. Camidge, D. R. et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol. 6, 774-780 (2011).
40. Lee, J. O. et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J. Thorac. Oncol. 6, 1474-1480 (2011).
41. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00932893 (2012).
42. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01154140 (2012).
43. Doebele, R. C. et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer http://dx.doi.org/ 10.1002/cncr.27409.
44. Cui, J. J. et al. Structure based drug design of crizotinib (PF02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342-6363 (2011).
45. Gambacorti-Passerini, C., Messa, C. & Pogliani, E. M. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364, 775-776 (2011).
46. Butrynski, J. E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727-1733 (2010).
47. Ou, S. H. et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
48. Lennerz, J. K. et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011).
49. Camidge, D. R. et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 29 (Suppl.), a2501 (2011).
50. Spigel, D. R. et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J. Clin. Oncol. 29 (Suppl.), a7505 (2011).
51. Matsumoto, D. C. et al. Effect on retinal function as a mechanism for vision disorders with crizotinib (PF02341066) [abstract]. Proc. 102nd Ann. Meeting Am. Assoc. Cancer Res. a4385 (2011).
52. Weickhardt, A. J. et al. Rapid onset hypogonadism secondary to crizotinib use in men with metastatic non-small cell lung cancer. Cancer 2012 (In press).
53. Ou, S. H., Azada, M., Dy, J. & Stiber, J. A. Asymptomatic profound sinus bradycardia (heart rate =45) in non-small cell lung cancer patients treated with crizotinib. J. Thorac. Oncol. 6, 2135-2137 (2011).
54. Tan, W. et al. Pharmacokinetics (PK) of PF02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a2596 (2010).
55. Costa, D. B. et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 29, e443-e445 (2011).
56. Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010).
57. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
58. Gorre, M. E. et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001). (Pubitemid 32743979)
59. Sasaki, T. et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051-6060 (2011).
60. Doebele, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012).
61. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra17 (2012).
62. Zhang, S. et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem. Biol. Drug Des. 78, 999-1005 (2011).
63. Heuckmann, J. M. et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res. 17, 7394-7401 (2011).
64. Sasaki, T. et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 70, 10038-10043 (2010).
65. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
66. Balak, M. N. et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494-6501 (2006). (Pubitemid 44799723)
67. Costa, D. B. et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin. Cancer Res. 14, 7060-7067 (2008).
68. von Bubnoff, N., Schneller, F., Peschel, C. & Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome- positive leukaemia to STI571: a prospective study. Lancet 359, 487-491 (2002). (Pubitemid 34164296)
69. Yun, C. H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070-2075 (2008).
70. Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
71. Becker, A. et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47, 2603-2606 (2011).
72. Parker, W. T. et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J. Clin. Oncol. 29, 4250-4259 (2011).
73. Katayama, R. et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl Acad. Sci. USA 108, 7535-7540 (2011).
74. Kris, M. G. et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC) [abstract]. J. Clin. Oncol. 29 (Suppl.), CRA7506 (2011).
75. Koivunen, J. P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008).
76. Singh, A. et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500 (2009).
77. Popat, S. et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J. Thorac. Oncol. 6, 1962-1963 (2011).
78. Makhnevych, T. & Houry, W. A. The role of Hsp90 in protein complex assembly. Biochim. Biophys. Acta 1823, 674-682 (2012).
79. Bonvini, P., Gastaldi, T., Falini, B. & Rosolen, A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 62, 1559-1566 (2002). (Pubitemid 34407823)
80. Normant, E. et al. The Hsp90 inhibitor IPI504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30, 2581-2586 (2011).
81. Sequist, L. V. et al. Activity of IPI504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined nonsmallcell lung cancer. J. Clin. Oncol. 28, 4953-4960 (2010).
82. Wong, K. et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 29 (Suppl.), a7500 (2011).
83. Chen, Z. et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 70, 9827-9836 (2010).
84. Knowlton, C. A., Brady, L. W. & Heintzelman, R. C. Radiotherapy in the treatment of gastrointestinal stromal tumors. Rare Tumors 3, e35 (2011).
85. Raut, C. P. et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. 24, 2325-2331 (2006). (Pubitemid 46630664)
86. Al-Batran, S. E. et al. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer 10, 145-152 (2007).
87. Stoica, G. E. et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276, 16772-16779 (2001).
88. Stoica, G. E. et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 277, 35990-35998 (2002).
89. McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389-3395 (2008).
90. Apperley, J. F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8, 1018-1029 (2007). (Pubitemid 47629897)
91. FDA. Highlights of prescribing information-Crizotinib [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202570s000lbl.pdf (2011).
92. Sugawara, E. et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer http://dx.doi.org/10.1002/cncr.27391.
93. Van Gaal, J. C. et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J. Clin. Oncol. 30, 308-315 (2012).
94. Bridge, J. A. et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol. 159, 411-415 (2001). (Pubitemid 32751070)
95. Colleoni, G. W. et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J. Pathol. 156, 781-789 (2000). (Pubitemid 30626935)
96. Camidge, D. R. et al. Correlations between the percentage of tumor cells showing an ALK gene rearrangement, ALK signal copy number and response to crizotinib therapy in ALK FISH positive nonsmall cell lung cancer. Cancer http://dx.doi.org/10.1002/cncr.27411.
97. Camidge, D. R., Hirsch, F. R., Varella-Garcia, M. & Franklin, W. A. Finding ALK-positive lung cancer: what are we really looking for? J. Thorac. Oncol. 6, 411-413 (2011).
98. Shaw, A. T., Solomon, B. & Kenudson, M. M. Crizotinib and testing for ALK. J. Natl Compr. Canc. Netw. 9, 1335-1341 (2011).
99. Horn, L. & Pao, W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 27, 4232-4235 (2009).